Cargando…

Early response predicts a sustained response to eluxadoline in patients with irritable bowel syndrome with diarrhoea in two Phase 3 studies

SUMMARY: BACKGROUND: The mixed μ‐ and κ‐opioid receptor agonist and δ‐opioid receptor antagonist, eluxadoline, is licensed in the USA for the treatment of irritable bowel syndrome with diarrhoea (IBS‐D), based on the results of two large Phase 3 clinical trials. AIM: To understand the time course of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chey, W. D., Dove, L. S., Andrae, D. A., Covington, P. S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2017
Materias:	Eluxadoline for Irritable Bowel Syndrome
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5413805/ https://www.ncbi.nlm.nih.gov/pubmed/28326568 http://dx.doi.org/10.1111/apt.14031

Ejemplares similares

Two microbiota subtypes identified in irritable bowel syndrome with distinct responses to the low FODMAP diet
por: Vervier, Kevin, et al.
Publicado: (2022)

Safety and tolerability of rifaximin for the treatment of irritable bowel syndrome without constipation: a pooled analysis of randomised, double‐blind, placebo‐controlled trials
por: Schoenfeld, P., et al.
Publicado: (2014)

Effects of baseline abdominal pain and bloating on response to lubiprostone in patients with irritable bowel syndrome with constipation
por: Chang, L., et al.
Publicado: (2016)

A Swedish national adoption study of risk of irritable bowel syndrome (IBS)
por: Waehrens, Rasmus, et al.
Publicado: (2017)

Faecal incontinence—the hidden scourge of irritable bowel syndrome: a cross-sectional study
por: Atarodi, Sima, et al.
Publicado: (2015)

Efficacy of individualised diets in patients with irritable bowel syndrome: a randomised controlled trial
por: Ali, Ather, et al.
Publicado: (2017)

Vitamin D associates with improved quality of life in participants with irritable bowel syndrome: outcomes from a pilot trial
por: Tazzyman, Simon, et al.
Publicado: (2015)

Double-blinded randomised placebo controlled trial of enterosgel (polymethylsiloxane polyhydrate) for the treatment of IBS with diarrhoea (IBS-D)
por: Howell, Carol Angela, et al.
Publicado: (2022)

Does Fibre-fix provided to people with irritable bowel syndrome who are consuming a low FODMAP diet improve their gut health, gut microbiome, sleep and mental health? A double-blinded, randomised controlled trial
por: Yan, Ran, et al.
Publicado: (2020)

Gut microbiome composition and risk factors in a large cross-sectional IBS cohort
por: Agnello, Melissa, et al.
Publicado: (2020)

Diet or medication in primary care patients with IBS: the DOMINO study - a randomised trial supported by the Belgian Health Care Knowledge Centre (KCE Trials Programme) and the Rome Foundation Research Institute
por: Carbone, Florencia, et al.
Publicado: (2022)

Development of a new version of the Bristol Stool Form Scale: translation, content validity, face validity, and reliability of the Persian version
por: Shokouhi, Nasim, et al.
Publicado: (2022)

Safety of Eluxadoline in Patients with Irritable Bowel Syndrome with Diarrhea
por: Cash, Brooks D, et al.
Publicado: (2017)

Effects of treatment with eluxadoline on abdominal pain in patients with IBS‐D: Additional post hoc analyses of Phase 3 trials
por: Lembo, Anthony J., et al.
Publicado: (2020)

Eluxadoline Efficacy in IBS-D Patients Who Report Prior Loperamide Use
por: Lacy, Brian E, et al.
Publicado: (2017)

Eluxadoline in the treatment of diarrhea-predominant irritable bowel syndrome
por: Özdener, Ayşe Elif, et al.
Publicado: (2017)

The impact of treatment with eluxadoline on health-related quality of life among adult patients with irritable bowel syndrome with diarrhea
por: Abel, Jessica L., et al.
Publicado: (2018)

Effect of Hepatic Impairment on Eluxadoline Pharmacokinetics
por: Marbury, Thomas C., et al.
Publicado: (2017)

Evaluation of Eluxadoline Effect on Cardiac Repolarization
por: Bonifacio, Laura, et al.
Publicado: (2018)

Spotlight on eluxadoline for the treatment of patients with irritable bowel syndrome with diarrhea
por: Fragkos, Konstantinos C
Publicado: (2017)

Clinical potential of eluxadoline in the treatment of diarrhea-predominant irritable bowel syndrome
por: Sobolewska-Włodarczyk, Aleksandra, et al.
Publicado: (2016)

Update on Eluxadoline for the Treatment of Irritable Bowel Syndrome with Diarrhea: Patient Selection and Perspectives
por: Liu, Rebecca, et al.
Publicado: (2020)

Preparation, Evaluation and Bioavailability Studies of Eudragit Coated PLGA Nanoparticles for Sustained Release of Eluxadoline for the Treatment of Irritable Bowel Syndrome
por: Anwer, Md. K., et al.
Publicado: (2017)

Irritant-induced Asthma Caused by Aerotoxic Syndrome
por: Roig, Jorge, et al.
Publicado: (2021)

Evaluation of the Irritable Bowel Syndrome Quality of Life (IBS-QOL) questionnaire in diarrheal-predominant irritable bowel syndrome patients
por: Andrae, David A, et al.
Publicado: (2013)

Eluxadoline Versus Antispasmodics in the Treatment of Irritable Bowel Syndrome: An Adjusted Indirect Treatment Comparison Meta-analysis
por: Qin, Di, et al.
Publicado: (2022)

Impact of patient and disease characteristics on the efficacy and safety of eluxadoline for IBS-D: a subgroup analysis of phase III trials
por: Lacy, Brian E., et al.
Publicado: (2019)

Efficacy and Safety of Eluxadoline in Patients With Irritable Bowel Syndrome With Diarrhea Who Report Inadequate Symptom Control With Loperamide: RELIEF Phase 4 Study
por: Brenner, Darren M., et al.
Publicado: (2019)

Improved work productivity and health-related quality of life in patients with irritable bowel syndrome with diarrhea receiving eluxadoline following inadequate response to loperamide
por: Brenner, Darren M, et al.
Publicado: (2021)

Bile acid diarrhoea: pathophysiology, diagnosis and management
por: Farrugia, Alexia, et al.
Publicado: (2020)

Using best practice to create a pathway to improve management of irritable bowel syndrome: aiming for timely diagnosis, effective treatment and equitable care
por: Williams, Marianne, et al.
Publicado: (2016)

Biomarkers of Therapeutic Response in the IL-23 Pathway in Inflammatory Bowel Disease
por: Cayatte, Corinne, et al.
Publicado: (2012)

Rifaximin is associated with modest, transient decreases in multiple taxa in the gut microbiota of patients with diarrhoea-predominant irritable bowel syndrome
por: Fodor, Anthony A., et al.
Publicado: (2018)

Association between Brachyspira and irritable bowel syndrome with diarrhoea
por: Jabbar, Karolina S, et al.
Publicado: (2021)

Eluxadoline-Loaded Eudragit Nanoparticles for Irritable Bowel Syndrome with Diarrhea: Formulation, Optimization Using Box–Behnken Design, and Anti-Diarrheal Activity
por: Anwer, Md. Khalid, et al.
Publicado: (2023)

Comparison of treatment effect between phase 2 and phase 3 trials in patients with inflammatory bowel disease
por: Wils, Pauline, et al.
Publicado: (2023)

Impact of comorbidities on anti-TNFα response and relapse in patients with inflammatory bowel disease: the VERNE study
por: Marin-Jimenez, Ignacio, et al.
Publicado: (2020)

The gut microbiome and irritable bowel syndrome
por: Menees, Stacy, et al.
Publicado: (2018)

Dysregulated long non-coding RNA in Sjögren’s disease impacts both interferon and adaptive immune responses
por: Joachims, Michelle L, et al.
Publicado: (2022)

Panenteric capsule endoscopy identifies proximal small bowel disease guiding upstaging and treatment intensification in Crohn's disease: A European multicentre observational cohort study
por: Tai, Foong Way D., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_evif2j73pthhlfbkc9ho6jg9t1